| Andy Nolen, Houston Drug Possession Defense Lawyer HUNDREDS OF CASES DISMISSED |
| HOUSTON DRUG CASE DEFENSE LAWYER OVER 15 YEARS CRIMINAL LAW EXPERIENCE LICENSED IN BOTH STATE AND FEDERAL COURT |
| One of the most experienced Houston defense lawyers, Attorney Andy Nolen, represents people who have been accused of a state crime or Houston law, including in communities such as League City, Angleton, Pearland, Alvin, Clear Lake, Sugar Land, The Woodlands, Baytown, Pasadena, Memorial, Spring Branch, River Oaks, West University, and Bellaire. Counties that Houston criminal attorney Andy Nolen serves include: Galveston County • Fort Bend County • Montgomery County • Brazoria County • Harris County. Cases handled include: Possession of Marijuana, Cocaine, Crystal Methamphetamine, Xanax, Prescription Drugs, Probation Violations, Theft, Shoplifting, Drunk Driving, Evading Arrest, and all other Felonies and Misdemeanors. |
| 15 Years Courtroom Experience as a Houston Drug Charge Lawyer |
| 713-697-4373 FREE CONSULTATION Flexible Appointments |
| VISIT OUR OTHER WEBSITES |
| Andy Nolen, Attorney at Law ...representing those accused of drug and alcohol cases Painkillers, Dangerous but less well known: |
| Pentazocine The effort to find an effective analgesic with less dependence-producing consequences led to the development of pentazocine (Talwin). Introduced as an analgesic in 1967, it was frequently encountered in the illicit trade, usually in combination with tripelennamine and placed into Schedule IV of the CSA in 1979. An attempt at reducing the abuse of this drug was made with the introduction of Talwin Nx. This product contains a quantity of antagonist (naloxone) sufficient to counteract the morphine-like effects of pentazocine if the tablets are dissolved and injected. Butorphanol While butorphanol can be made from thebaine, it is usually manufactured synthetically. It was initially available in injectable formulations for human (Stadol) and veterinary (Torbugesic and Torbutrol) use. More recently, a nasal spray (Stadol) became available, and significant diversion and abuse of this product led to the 1997 control of butorphanol in Schedule IV of the CSA. Butorphanol is a clear example of a drug gaining favor as a drug of abuse only after it became available in a form that facilitated greater ease of administration (nasal spray vs. injection). |